Alexion touts early 'proof-of-concept' data for Neurimmune antibody in ATTR cardiomyopathy
Alexion and its partners at Neurimmune have offered a first look into their Phase I candidate for transthyretin amyloid cardiomyopathy, touting early biomarker data that suggest the antibody did what it’s designed to do: clear amyloid from the heart.
The AstraZeneca subsidiary first teamed up with Neurimmune in early 2022, paying $30 million upfront to license NI006, for which a Phase I trial was already underway in Europe.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
